Pédiatrie Tumeurs solides CRISP (IC 2017-08 / ITCC 053) A phase 1B of crizotinib either in combination or as single agent in pediatric patients with ALK, ROS1 or MET positive malignancies. Paris ISABELLE AERTS
Recherches "plusieurs pathologies" DERMACLIC (IC 2019-12) Study on skin toxicities induced by cancer treatments Paris
Sein métastatique RH+ DOLAF An International Multicenter Phase II Trial of Durvalumab (MEDI4736) Plus OLAparib Plus Fulvestrant in Metastatic or Locally Advanced ER-positive, HER2-negative Breast Cancer Patients Selected Using Criteria That Predict Sensitivity to Olaparib Saint-Cloud
Pédiatrie Tumeurs solides LYNPARZA (D0816C000025) A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety;and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients with;Solid Tumours Paris ISABELLE AERTS
Recherches "plusieurs pathologies" MCLA-128-CL01 A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Saint-Cloud
Pédiatrie Tumeurs solides MUCILA Multicenter double blind randomized placebo-controlled trial assessing the efficacy of low-level laser therapy in the prevention of chemotherapy-induced mucositis in children and young adults treated for a tumoral disease. Paris
Prostate TEMPOS (GETUG P14) Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy Paris, Saint-Cloud
Sein métastatique RH+ AMBRE OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Pédiatrie Tumeurs solides INFORM2 - NIVENT (IC 2018-07) INFORM2 Exploratory Multinational Phase I/II Combination Study of Nivolumab and Entinostat in Children and Adolescents With Refractory High-risk Malignancies Paris GUDRUN SCHLEIERMACHER
Appareil Digestif PERSPECTIVE (MS202202-0002) A Phase II Single-Arm Study to Investigate Tepotinib Combined With Cetuximab in RAS/BRAF Wild-Type Left-Sided mCRC Patients Having Acquired Resistance to Anti-EGFR Antibody Targeting Therapy Due to MET Amplification (PERSPECTIVE) Saint-Cloud